Clinical trial
A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (> 5 Days - PAL).
NCT02364791 is registered in ClinicalTrials.gov with National Cancer Institute, Naples as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase II Prospective, Single Blinded, Randomized Trial of Hemopatch Compared to Standard Techniques to Achieve Air Leak Control After Complex Thoracic Surgical Procedures on High Risk Population for Prolonged Air Leak (> 5 Days - PAL).
- Lead sponsor
- National Cancer Institute, Naples
- Phase
- Phase 2
- Overall status
- Unknown status
- Start date
- February 28, 2015
- Completion date
- December 31, 2024
- Enrollment
- 120 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
post-operative thoracic air leak, thoracic surgery lung